BullFrog AI Technology Licensed from Johns Hopkins University APL Named Finalist in R&D 100 Awards
- Proprietary technology recognized as leading-edge library for solving complex data challenges
- bfLEAP™ AI platform aims to improve drug development process and design of clinical trials
- None.
Proprietary Machine Learning Technology Powering bfLEAP™ Drug Discovery Platform Among Best in IT/Electrical Category
GAITHERSBURG, Md., Aug. 23, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a precision medicine company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced that its machine learning/artificial intelligence technology, exclusively licensed from the Johns Hopkins University Applied Physics Lab (APL), has been selected as a finalist in the IT/Electrical category for the R&D 100 Awards. The designation recognizes APL’s Prometheus/Euclid/Seagull algorithm suite as a leading-edge library integrating probabilistic modeling, graph analysis, and time series analysis to solve complex data challenges.
BullFrog AI’s proprietary bfLEAP™ AI platform leverages the Prometheus/Euclid/Seagull algorithm suite with an aim to enable clients to make discoveries and predictions from clinical and real world data sets with a focus on improving and streamlining the drug development process and the design of clinical trials. Prometheus/Euclid/Seagull algorithm suite’s key strengths include scalability for shallow and wide to large, high-dimensional datasets, handling missing information, and versatility across domains. Prometheus offers parallelizable probabilistic models excelling in anomaly detection and clustering. Euclid stands out with automated data fusion, link inference, and network flow analysis. Seagull excels in enriching and correlating time series data for anomaly detection. The suite's modular structure ensures adaptability and applicability across domains.
"We are honored that the proprietary machine learning technology for which we hold exclusive global licensing rights from APL has been named a finalist for the R&D 100 Awards,” stated Vin Singh, CEO of BullFrog AI. “We believe that any powerful solution for the pharmaceutical industry needs to lead with great technology and this designation further validates the best-in-class capability of our bfLEAP™ AI platform to glean insights from incomplete data sets, in a transparent and explainable manner, that reveal patterns and relationships to better predict how patients and drug compounds will respond in clinical trials.”
About BullFrog AI
BullFrog AI is a precision medicine company using AI and machine learning to enable the successful development of pharmaceuticals and biologics by predicting which patients will respond to therapies in development. Through its collaborations with leading research institutions, including Johns Hopkins University, BullFrog AI is at the forefront of AI-driven drug development using its proprietary bfLEAP™ artificial intelligence platform. BullFrog AI is deploying bfLEAP™ for use at several critical stages of development with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics.
For more information visit BullFrog AI at:
Website: https://bullfrogai.com
LinkedIn: https://www.linkedin.com/company/bullfrogai/
Safe Harbor Statement
This press release contains forward-looking statements. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.
Contact:
Investors
Dave Gentry
RedChip Companies, Inc.
BFRG@redchip.com
800-733-2447
Media
Tiberend Strategic Advisors, Inc.
Eric Reiss
Ereiss@tiberend.com
802-249-1136
Dave Schemelia
Dschemelia@tiberend.com
609-468-9325
SOURCE: BullFrog AI Holdings, Inc.
